Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07601100 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

Study acronym: IsaIberVD
StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jun 26, 2026 to Sep 3, 2026 Site contacts updated at 2 of 2 sites · Study title shortened, about 2 wordsv3 Show 2 more changesShow less
    • Site contacts updated at 2 of 2 sites
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Primary endpoint(s) modified Start date: May 26, 2026 to Jun 26, 2026 · Trial arms changed: 2 → 6 · Interventions: Arm A: Isatuximab, iberdomide, bortezomib, and dexamethasone with a standard-intensity bortezomib and dexamethasone schedule (Drug), Arm B… to Bortezomib (Drug), Dexamethesone (Drug), Iberdomide (Drug), Isatuximab (Drug) · 3 morev2 Show 6 more changesShow less
    • Start date: May 26, 2026 to Jun 26, 2026
    • Trial arms changed: 2 → 6
    • Interventions: Arm A: Isatuximab, iberdomide, bortezomib, and dexamethasone with a standard-intensity bortezomib and dexamethasone schedule (Drug), Arm B… to Bortezomib (Drug), Dexamethesone (Drug), Iberdomide (Drug), Isatuximab (Drug)
    • Secondary endpoints: 10 to 9
    • Study description expanded, about 22 words
    • Study title shortened, about 15 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is to evaluate the combination of isatuximab, iberdomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma participants who are transplant ineligible or not intended for upfront transplant. The names of the study drugs used in this research study are: isatuximab, iberdomide, bortezomib dexamethasone
Trial Details
NCT Number NCT07601100
Lead Sponsor Dana-Farber Cancer Institute
Conditions Newly Diagnosed Multiple Myeloma
Enrollment 88 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov